A Study to Evaluate Immune Markers in Patients with Renal Cell Cancer

Overview

About this study

The objectives of this study are to measure baseline immune markers and peripheral blood mononuclear cell (PBMC) characteristics in RCC patients, to measure post-ablative therapy immune markers and PBMC characteristics, to compare effects of SBRT versus PCA on immune markers and PBMC characteristics, and to assess impact of post-treatment markers on time to disease progression and levels of markers at time of disease progression.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Histological diagnosis of primary RCC

- Histological or radiographic diagnosis of metastatic RCC

- Age >= 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status 0-3

- Feasible vascular access as determined by study staff

- Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)

- Provide written informed consent

- Willing to consent to research blood draws

- Willing to return to enrolling institution for follow-up

Exclusion Criteria:

- Prior local treatment of the index metastatic lesion

- Pregnant or nursing women

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for study entry

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/29/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Bradley Stish, M.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Cancer Center Clinical Trials Referral Office (855) 776-0015

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Stish, M.D.

Closed-enrolling by invitation

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Clinical Trials